Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.42 |
| ▸ | TUBB | P07437 | 3/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.42 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14380906 | 0.79 | MKNK1 (0.40) | PYGMVCPDAPK3MAP4K4PRKACA | |
| SCHEMBL11097221 | 0.74 | CSNK1A1 (0.61) | VCPDAPK3MAP4K4PRKACALTK | |
| SCHEMBL7168183 | 0.72 | NOS2 (0.53) | PRKACAESR2NOS2 | |
| SCHEMBL2309144 | 0.72 | MAPK1 (0.61) | PRKACAESR2NOS2 | |
| SCHEMBL3786377 | 0.71 | MTOR (0.67) | PIK3CDPIK3CAPIK3CBMTORPIK3CG | |
| Hydrochloric Acid SCHEMBL7167676 | 0.71 | NOS2 (0.52) | PRKACAESR2NOS2 | |
| SCHEMBL7294885 | 0.71 | PDPK1 (0.44) | VCPPDE10ADAPK3MAP4K4PRKACA | |
| SCHEMBL1091636 | 0.70 | ALDH1A1 (0.58) | PLA2G7VCP | |
| SCHEMBL722560 | 0.70 | RAB9A (0.59) | PLA2G7MTOR | |
| SCHEMBL5945572 | 0.70 | ESR1 (0.54) | PRKACAESR2NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137784-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-09-26 | — | — | US | claimed |
| US-20020049246-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-04-25 | — | — | US | claimed |
| EP-1091942-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-04-18 | — | — | EP | claimed |
| WO-2000001676-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2000-01-13 | — | — | WO | claimed |
| US-6569880-B2 | Guanidine derivatives | NEUROSEARCH A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| US-20020137784-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-09-26 | — | — | US | disclosed |
| US-6380180-B1 | BENZIMIDAZOLE COMPOUNDS FOR TREATMENT OF ASTHMA, VASOSPASM, MEMORY LOSS, MIGRAINE AND OTHERS DISEASES ASSOCIATED WITH POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20020049246-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-04-25 | — | — | US | disclosed |
| EP-1091942-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-04-18 | — | — | EP | disclosed |
| US-6194447-B1 | ASTHMA, ANTICONVULSANTS, COGNITION ACTIVATORS, BRAIN DISORDERS, PSYCHOLOGICAL DISORDERS, CARDIOVASCULAR DISORDERS,GASTROINTESTINAL DISORDERS | NEUROSEARCH A/S (DK) | 2001-02-27 | — | — | US | disclosed |
| WO-2000001676-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137784-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | PYGM 251/4885TUBB4A 1771/4885TUBB 1166/4885 |
| US-20020049246-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | PYGM 251/4885TUBB4A 1771/4885TUBB 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.